{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:28:58Z","timestamp":1792956538391,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"US Army Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Defense Medical under","award":["W911QY-16-9-0001"],"award-info":[{"award-number":["W911QY-16-9-0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Efficacious therapeutics for Ebola virus disease are in great demand. Ebola virus infections mediated by mucosal exposure, and aerosolization in particular, present a novel challenge due to nontypical massive early infection of respiratory lymphoid tissues. We performed a randomized and blinded study to compare outcomes from vehicle-treated and remdesivir-treated rhesus monkeys in a lethal model of infection resulting from aerosolized Ebola virus exposure. Remdesivir treatment initiated 4\u00a0days after exposure was associated with a significant survival benefit, significant reduction in serum viral titer, and improvements in clinical pathology biomarker levels and lung histology compared to vehicle treatment. These observations indicate that remdesivir may have value in countering aerosol-induced Ebola virus disease.<\/jats:p>","DOI":"10.1038\/s41598-021-98971-0","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:30:41Z","timestamp":1632997841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus"],"prefix":"10.1038","volume":"11","author":[{"given":"Travis K.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Stuthman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Van Tongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"98971_CR1","unstructured":"World Health Organization, Situation report. Ebola Virus Disease. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208883\/ebolasitrep_10Jun2016_eng.pdf;jsessionid=4F7DFD58B3A8FDF69F885F6DF11F4E60?sequence=1. 2016."},{"key":"98971_CR2","unstructured":"World Health Organization, Ebola in the Democratic Republic of Congo. Health Emergency Update. https:\/\/www.who.int\/emergencies\/diseases\/ebola\/drc-2019. 2020."},{"issue":"7551","key":"98971_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/521137a","volume":"521","author":"E Check Hayden","year":"2015","unstructured":"Check Hayden, E. Ebola failures prompt WHO rethink. Nature 521(7551), 137 (2015).","journal-title":"Nature"},{"issue":"3","key":"98971_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1017\/S1049023X15004689","volume":"30","author":"J Levett","year":"2015","unstructured":"Levett, J. Disastrous events and political failures. Prehosp. Disaster Med. 30(3), 227\u2013228 (2015).","journal-title":"Prehosp. Disaster Med."},{"key":"98971_CR5","doi-asserted-by":"crossref","unstructured":"Ebola: a failure of international collective action. Lancet, 2014. 384(9944):637.","DOI":"10.1016\/S0140-6736(14)61377-5"},{"issue":"12","key":"98971_CR6","first-page":"827","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. FDA approves antibody cocktail for Ebola virus. Nat. Rev. Drug Discov. 19(12), 827 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"98971_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","volume":"181","author":"E Ollmann Saphire","year":"2020","unstructured":"Ollmann Saphire, E. A vaccine against ebola virus. Cell 181(1), 6 (2020).","journal-title":"Cell"},{"key":"98971_CR8","unstructured":"The U.S. Food and Drug Administration, FDA Approves Treatment for Ebola Virus. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-treatment-ebola-virus. 2020."},{"key":"98971_CR9","first-page":"449","volume-title":"Fields Virology (Emerging Viruses)","author":"JH Kuhn","year":"2020","unstructured":"Kuhn, J. H. et al. Filoviridae. In Fields Virology (Emerging Viruses) (eds Howley, P. M. et al.) 449\u2013503 (Wolters Kluwer Health\/Lippincott Williams & Wilkins, 2020)."},{"issue":"2","key":"98971_CR10","doi-asserted-by":"publisher","first-page":"e00137","DOI":"10.1128\/mBio.00137-15","volume":"6","author":"MT Osterholm","year":"2015","unstructured":"Osterholm, M. T. et al. Transmission of Ebola viruses: What we know and what we do not know. MBio 6(2), e00137 (2015).","journal-title":"MBio"},{"key":"98971_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v11100940","volume":"11","author":"SD Judson","year":"2019","unstructured":"Judson, S. D. & Munster, V. J. Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses 11, 10 (2019).","journal-title":"Viruses"},{"key":"98971_CR12","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1136\/bmj.g6200","volume":"349","author":"M McCarthy","year":"2014","unstructured":"McCarthy, M. Texas healthcare worker is diagnosed with Ebola. BMJ 349, 6200 (2014).","journal-title":"BMJ"},{"issue":"8","key":"98971_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ajic.2015.05.006","volume":"43","author":"M Klompas","year":"2015","unstructured":"Klompas, M. & Yokoe, D. S. The Ebola transmission paradox. Am. J. Control 43(8), 786\u2013787 (2015).","journal-title":"Am. J. Control"},{"issue":"5","key":"98971_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/JOM.0000000000000448","volume":"57","author":"RM Jones","year":"2015","unstructured":"Jones, R. M. & Brosseau, L. M. Aerosol transmission of infectious disease. J. Occup. Environ. Med. 57(5), 501\u2013508 (2015).","journal-title":"J. Occup. Environ. Med."},{"issue":"11","key":"98971_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1086\/503836","volume":"42","author":"P Formenty","year":"2006","unstructured":"Formenty, P. et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin. Infect. Dis. 42(11), 1521\u20131526 (2006).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"98971_CR16","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1086\/520545","volume":"196","author":"DG Bausch","year":"2007","unstructured":"Bausch, D. G. et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196(Suppl 2), S142\u2013S147 (2007).","journal-title":"J. Infect. Dis."},{"issue":"5","key":"98971_CR17","first-page":"1531","volume":"109","author":"TJ Piercy","year":"2010","unstructured":"Piercy, T. J. et al. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J. Appl. Microbiol. 109(5), 1531\u20131539 (2010).","journal-title":"J. Appl. Microbiol."},{"issue":"8","key":"98971_CR18","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.biocel.2005.02.018","volume":"37","author":"M Bray","year":"2005","unstructured":"Bray, M. & Geisbert, T. W. Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol. 37(8), 1560\u20131566 (2005).","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"8991\u20138992","key":"98971_CR19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0140-6736(95)92841-3","volume":"346","author":"N Jaax","year":"1995","unstructured":"Jaax, N. et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346(8991\u20138992), 1669\u20131671 (1995).","journal-title":"Lancet"},{"issue":"3","key":"98971_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0300985812469636","volume":"50","author":"NA Twenhafel","year":"2013","unstructured":"Twenhafel, N. A. et al. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet. Pathol. 50(3), 514\u2013529 (2013).","journal-title":"Vet. Pathol."},{"issue":"11","key":"98971_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.micinf.2011.05.002","volume":"13","author":"DS Reed","year":"2011","unstructured":"Reed, D. S. et al. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: Differences in disease course and clinical pathology. Microbes Infect. 13(11), 930\u2013936 (2011).","journal-title":"Microbes Infect."},{"key":"98971_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v12010092","volume":"12","author":"T Warren","year":"2020","unstructured":"Warren, T. et al. Characterization of Ebola virus disease (EVD) in rhesus monkeys for development of EVD therapeutics. Viruses 12, 1 (2020).","journal-title":"Viruses"},{"issue":"6","key":"98971_CR23","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","volume":"163","author":"TW Geisbert","year":"2003","unstructured":"Geisbert, T. W. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163(6), 2347\u20132370 (2003).","journal-title":"Am. J. Pathol."},{"issue":"52","key":"98971_CR24","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","volume":"26","author":"TW Geisbert","year":"2008","unstructured":"Geisbert, T. W. et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26(52), 6894\u20136900 (2008).","journal-title":"Vaccine"},{"issue":"4","key":"98971_CR25","first-page":"227","volume":"76","author":"E Johnson","year":"1995","unstructured":"Johnson, E. et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76(4), 227\u2013236 (1995).","journal-title":"Int. J. Exp. Pathol."},{"issue":"Suppl 2","key":"98971_CR26","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1086\/520589","volume":"196","author":"T Larsen","year":"2007","unstructured":"Larsen, T. et al. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J. Infect. Dis. 196(Suppl 2), S323\u2013S328 (2007).","journal-title":"J. Infect. Dis."},{"key":"98971_CR27","unstructured":"Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ, 1978. 56(2): p. 271\u201393."},{"key":"98971_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fimmu.2020.00105","volume":"11","author":"ER Aguilera","year":"2020","unstructured":"Aguilera, E. R. & Lenz, L. L. Inflammation as a modulator of host susceptibility to pulmonary influenza, pneumococcal, and co-infections. Front. Immunol. 11, 105 (2020).","journal-title":"Front. Immunol."},{"key":"98971_CR29","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541 (2019).","journal-title":"Antiviral Res."},{"key":"98971_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1126\/scitranslmed.aau9242","volume":"11","author":"MK Lo","year":"2019","unstructured":"Lo, M. K. et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 11, 494 (2019).","journal-title":"Sci. Transl. Med."},{"key":"98971_CR31","doi-asserted-by":"publisher","first-page":"43395","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395 (2017).","journal-title":"Sci. Rep."},{"key":"98971_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, 396 (2017).","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"98971_CR33","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel, D. et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J. Med. Chem. 60(5), 1648\u20131661 (2017).","journal-title":"J. Med. Chem."},{"issue":"7594","key":"98971_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531(7594), 381\u2013385 (2016).","journal-title":"Nature"},{"key":"98971_CR35","first-page":"2","volume":"2","author":"DP Porter","year":"2020","unstructured":"Porter, D. P. et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus. J. Infect. Dis. 2, 2 (2020).","journal-title":"J. Infect. Dis."},{"issue":"8","key":"98971_CR36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3201\/eid2308.170029","volume":"23","author":"RB Reisler","year":"2017","unstructured":"Reisler, R. B. et al. Clinical laboratory values as early indicators of Ebola virus infection in nonhuman primates. Emerg. Infect. Dis. 23(8), 1316\u20131324 (2017).","journal-title":"Emerg. Infect. Dis."},{"issue":"6279","key":"98971_CR37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351(6279), 1339\u20131342 (2016).","journal-title":"Science"},{"issue":"10174","key":"98971_CR38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","volume":"393","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski, M. R. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study. Lancet 393(10174), 889\u2013898 (2019).","journal-title":"Lancet"},{"issue":"5","key":"98971_CR39","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","volume":"218","author":"KE Pascal","year":"2018","unstructured":"Pascal, K. E. et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J. Infect. Dis. 218(5), S612\u2013S626 (2018).","journal-title":"J. Infect. Dis."},{"issue":"8","key":"98971_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","volume":"18","author":"S Sivapalasingam","year":"2018","unstructured":"Sivapalasingam, S. et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: A randomised, first-in-human phase 1 study. Lancet Infect. Dis. 18(8), 884\u2013893 (2018).","journal-title":"Lancet Infect. Dis."},{"issue":"7520","key":"98971_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520), 47\u201353 (2014).","journal-title":"Nature"},{"issue":"24","key":"98971_CR42","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381(24), 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"98971_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pathogens9100850","volume":"9","author":"S Jain","year":"2020","unstructured":"Jain, S., Khaiboullina, S. F. & Baranwal, M. Immunological perspective for ebola virus infection and various treatment measures taken to fight the disease. Pathogens 9, 10 (2020).","journal-title":"Pathogens"},{"issue":"9","key":"98971_CR44","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1473-3099(20)30282-6","volume":"20","author":"PL Iversen","year":"2020","unstructured":"Iversen, P. L. et al. Recent successes in therapeutics for Ebola virus disease: no time for complacency. Lancet Infect. Dis. 20(9), e231\u2013e237 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"98971_CR45","unstructured":"US Food and Drug Administration, First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. 2019."},{"key":"98971_CR46","unstructured":"US Food and Drug Administration, FDA Approves First Treatment for Ebola Virus. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus. 2020."},{"issue":"15","key":"98971_CR47","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"Group","year":"2016","unstructured":"Group et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375(15), 1448\u20131456 (2016).","journal-title":"N. Engl. J. Med."},{"key":"98971_CR48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/srep00811","volume":"2","author":"HM Weingartl","year":"2012","unstructured":"Weingartl, H. M. et al. Transmission of Ebola virus from pigs to non-human primates. Sci. Rep. 2, 811 (2012).","journal-title":"Sci. Rep."},{"issue":"3","key":"98971_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","volume":"96","author":"JS Munger","year":"1999","unstructured":"Munger, J. S. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96(3), 319\u2013328 (1999).","journal-title":"Cell"},{"issue":"4","key":"98971_CR50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.immuni.2006.02.008","volume":"24","author":"K Takabayshi","year":"2006","unstructured":"Takabayshi, K. et al. Induction of a homeostatic circuit in lung tissue by microbial compounds. Immunity 24(4), 475\u2013487 (2006).","journal-title":"Immunity"},{"issue":"1","key":"98971_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Primers 6(1), 13 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"13","key":"98971_CR52","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb, Y. N. Remdesivir: First approval. Drugs 80(13), 1355\u20131363 (2020).","journal-title":"Drugs"},{"issue":"12","key":"98971_CR53","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 117(12), 6771\u20136776 (2020).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"98971_CR54","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.3390\/v6114666","volume":"6","author":"TK Warren","year":"2014","unstructured":"Warren, T. K. et al. Euthanasia assessment in ebola virus infected nonhuman primates. Viruses 6(11), 4666\u20134682 (2014).","journal-title":"Viruses"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98971-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:02:04Z","timestamp":1670083324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98971"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98971-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.B., T.C., and D.P.P. are current employees, and may be shareholders, of Gilead Sciences. All other authors report no potential conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19458"}}